{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:18:44Z","timestamp":1779322724515,"version":"3.51.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1097\/md.0000000000007445","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T14:15:03Z","timestamp":1500473703000},"page":"e7445","source":"Crossref","is-referenced-by-count":13,"title":["An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China"],"prefix":"10.1097","volume":"96","author":[{"given":"Bin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Te","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-19-20210226","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"R2-19-20210226","first-page":"721","article-title":"Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China","volume":"30","author":"Wang","year":"2009","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R3-19-20210226","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"R4-19-20210226","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"key":"R5-19-20210226","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"key":"R6-19-20210226","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/0284186X.2010.495132","article-title":"Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib\u2014a Swedish model application","volume":"49","author":"Ghatnekar","year":"2010","journal-title":"Acta Oncol"},{"key":"R7-19-20210226","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clinthera.2014.02.008","article-title":"Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand","volume":"36","author":"Kulpeng","year":"2014","journal-title":"Clin Ther"},{"key":"R8-19-20210226","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","article-title":"Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia","volume":"14","author":"Hoyle","year":"2011","journal-title":"Value Health"},{"key":"R9-19-20210226","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1524-4733.2010.00771.x","article-title":"What do international pharmacoeconomic guidelines say about economic data transferability?","volume":"13","author":"Barbieri","year":"2010","journal-title":"Value Health"},{"key":"R10-19-20210226","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"key":"R11-19-20210226","first-page":"889","article-title":"Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib","volume":"33","author":"Huang","year":"2012","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R12-19-20210226","first-page":"1545","article-title":"Nilotinib treatment for patients with imatinib-resistant or intolerant chronic myeloid leukemia","volume":"22","author":"Pan","year":"2014","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"R13-19-20210226","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"R14-19-20210226","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"R15-19-20210226","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"R16-19-20210226","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"R17-19-20210226","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/asheducation-2013.1.176","article-title":"Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice","volume":"2013","author":"Oehler","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"R18-19-20210226","first-page":"633","article-title":"The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition).","volume":"37","author":"Chinese Society of Hematology","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R19-19-20210226","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta11450","article-title":"The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.","volume":"11","author":"Garside","year":"2007","journal-title":"Health Technol Assess"},{"key":"R20-19-20210226","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"R21-19-20210226","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-8722-6-54","article-title":"Biomarkers for determining the prognosis in chronic myelogenous leukemia","volume":"6","author":"Sweet","year":"2013","journal-title":"J Hematol Oncol"},{"key":"R22-19-20210226","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3109\/10428194.2013.772607","article-title":"Surrogate end points for long-term outcomes in chronic myeloid leukemia","volume":"54","author":"Akwaa","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R23-19-20210226","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-2\u2032deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"R28-19-20210226","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","article-title":"Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?","volume":"7","author":"Eichler","year":"2004","journal-title":"Value Health"},{"key":"R29-19-20210226","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O","article-title":"Development of WHO guidelines on generalized cost-effectiveness analysis","volume":"9","author":"Murray","year":"2000","journal-title":"Health Econ"},{"key":"R30-19-20210226","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"R31-19-20210226","doi-asserted-by":"crossref","first-page":"11A","DOI":"10.1182\/blood.V104.11.23.23","article-title":"Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials","volume":"104","author":"Silver","year":"2004","journal-title":"Blood"},{"key":"R32-19-20210226","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1517\/14656566.2011.597741","article-title":"The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose","volume":"12","author":"Breccia","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R33-19-20210226","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/aps.2010.79","article-title":"Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"R34-19-20210226","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R35-19-20210226","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"R36-19-20210226","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"R37-19-20210226","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"R38-19-20210226","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.3816\/CLM.2007.s.010","article-title":"Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors","volume":"7","author":"Atallah","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"R39-19-20210226","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","article-title":"A multinational study of health state preference values associated with chronic myelogenous leukemia","volume":"13","author":"Szabo","year":"2010","journal-title":"Value Health"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:54:23Z","timestamp":1620960863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201707210-00019"}},"subtitle":["A CHEERS-compliant article"],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":35,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007445","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}